The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Salarius Pharmaceuticals, Inc(NASDAQ:SLRX) 
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ...
Share this website to your friends
Salarius Pharmaceuticals Days Payable Outstanding ttm (DPO)
Salarius Pharmaceuticals Days Receivable Outstanding ttm (DSO)
Salarius Pharmaceuticals Op Cashflow Per Share ttm
Salarius Pharmaceuticals Free Cashflow Per Share ttm
Salarius Pharmaceuticals Cash Per Share ttm
Salarius Pharmaceuticals P/S ratio ttm
Salarius Pharmaceuticals (GAAP) P/E ratio ttm
Salarius Pharmaceuticals P/B ratio ttm
No extra charts and metrics for this ticker.